

References

1. Anna D. Kosinska, Ejuan Zhang, Mengji Lu, and Michael Roggendorf ,Therapeutic Vaccination in Chronic Hepatitis B: Preclinical Studies in the Woodchuck Hepatitis Research and Treatment Volume 2010 (2010), Article ID 817580, 17 pages doi:10.1155/2010/817580
2. Arthur Clifton Guyton and John E. Hall Textbook of Medical Physiology twelfth edition Philadelphia, PA : Saunders Elsevier, ©2006.
3. Bader T, Korba B. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. *Antiviral Res.* 2010 Jun;86(3):241-5.
4. Behal R, Jain R, Behal KK, et al. Seroprevalence and risk factors for hepatitis B virus infection among general population in northern India. *Arq Gastroenterol* 2008; 45(2):137-140.
5. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. *Gastroenterology* 2010; 139:1207–1217.
6. Buster EH, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. *Gastroenterology* 2008; 135(2): 459–467.
7. Chang TT, Lai CL, Kew Yoon S et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. *Hepatology* 2010; 51(2): 422–430.
8. Chanunta Hongthanakorn, MD Anna S.F. Lok, MD* New Pharmacologic Therapies in Chronic Hepatitis B *Gastroenterology Clinics - Volume 39, Issue 3 (September 2010) - Copyright © 2010 W. B. Saunders Company*
9. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. *Hepatology* 2010; 51(2): 435–444.
10. Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing Levels of Hepatitis B Surface Antigen Predict Hepatitis B Surface Antigen Seroclearance in

- Patients With Inactive Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2011 Sep 3.
11. Cornberg M, Protzer U, Petersen J, et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline. Z Gastroenterol 2011;49:871-930
 12. Courtney M. Townsend, Jr., MD, R. Daniel Beauchamp, MD, B. Mark Evers, MD and Kenneth L. Mattox, MD THE BIOLOGICAL BASIS OF MODERN SURGICAL PRACTICE Sabiston Textbook of Surgery, 19th Edition
 13. Daniel Grimm, Robert Thimme, and Hubert E. Blum ' HBV life cycle and novel drug targets Hepatol Int. 2011 June; 5(2): 644–653. Published online 2011 March 8. doi: 10.1007/s12072-011-9261-3 Copyright © Asian Pacific Association for the Study of the Liver 2011
 14. David H. Alpers., William F. Stenson, Beth Taylor, Dennis M. Bier, Manual of nutritional therapeutics 5th edition March 2008 Publisher Lippincott Williams & Wilkins.
 15. Deirdre A. Kelly, Diseases of the liver and Biliary system in children 3rd edition, incorporated by Wiley & Sons, (2008)
 16. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500.
 17. Edward C. Doo, MD Marc G. Ghany, MD, MHS Hepatitis B Virology for Clinicians ; Clinics in Liver Disease - Volume 14, Issue 3 (August 2010) .
 18. Elaine N. Marieb & Katja Hoehn., Anatomy & Physiology of the liver, Human Anatomy & Physiology 7 edition (January 14, 2006) Benjamin Cummings
 19. Elizabeth W. Hwang, MD, Ramsey Cheung, MD Global Epidemiology of Hepatitis B Virus (HBV) Infection [N A J Med Sci. 2011;4(1):7-13.]... Vol.4 Issue 3 – Jul 2011 Vol.4 Issue 3 – Jul 2011
 20. Erwin Kuntz, Hans-Dieter Kuntz . Hepatology Textbook and Atlas 3rd edition., Lipid, October 2008 Springer-Verlag New York.

21. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. *J Hepatol* 2009; 50(2): 227–242.
22. European Centre for Disease Control and Prevention (ECDC). Annual epidemiological report on communicable diseases in Europe. ECDC 2007:301. http://www.ecdc.europa.eu/pdf/ECDC_epi_report_2007.pdf. Accessed July 19, 2010.
23. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010; Epub Jun 17.
24. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. *Hepatology* 2009; 5(Suppl.): S185–95.
25. Gerald L. Mandell, MD, MACP, John E. Bennett, MD, MACP, and Raphael Dolin, MD Mandell Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. Copyright © 2009 Churchill Livingstone, An Imprint of Elsevier
26. Guner R, Karahocagil M, Buyukberber M, et al. Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection. *Eur J Gastroenterol Hepatol*. 2011;23:1185-91.
27. Hadziyannis S., Sevastianos V., Rapti I.: Outcome of HBeAg-negative chronic hepatitis B (CHB) 5 years after discontinuation of long term adefovir dipivoxil (ADV) treatment. *J Hepatol* 50. (S1): S9-S10.2009.
28. Han G, Zhao W, Cao M et al. A prospective and open-label study for the efficacy and safety of telbivudine (LdT) in pregnancy for the prevention of perinatal transmission of hepatitis B virus (HBV) to the infants. Presented at: 61st Annual Meeting of the American Association for the Study of Liver Disease. Abstract 212, Boston, MA, USA, 30 October - 2 November 2010.
29. Hank S. Wang, MD Steven-Huy B. Han, MD, AGAF* Management of Hepatitis B in Special Patient Populations ,Clinics in Liver Disease - Volume 14, Issue 3 (August 2010) - Copyright © 2010 W. B. Saunders Company - About This Journal Add Journals Issue Alert

30. Hank S. Wang, MD Steven-Huy B. Han, MD, AGAF* Management of Hepatitis B in Special Patient Populations Clinics in Liver Disease - Volume 14, Issue 3 (August 2010) - Copyright © 2010 W. B. Saunders Company - About This Journal Add Journals Issue Alert
31. Harold Ellis Clinical Anatomy 11 th edition 2006 : liver anatomy .Wiley-Blackwell 2006.
32. Hejun Yuan; William M. Lee Update of Chronic Hepatitis B Posted: 05/09/2011; Curr Opin Gastroenterol. 2011;27(3):217-223. © 2011 Lippincott Williams & Wilkins .
33. Hellan Kwon & Anna S. Lok . Hepatitis B therapy Nature Reviews Gastroenterology and Hepatology 8, 275-284 (May 2011) doi:10.1038/nrgastro.2011.33
34. Hin Hin Ko; David K. H. Wong; Jenny Heathcote(Management of Hepatitis B), Posted: 05/04/2011; Clin Gastroenterol Hepatol. 2011;9(5):385-391.
35. Irene N. Rapti; Stephanos J. Hadziyannis, MD Treatment of Special Populations With Chronic Hepatitis B Infection CME .From Expert Review of Gastroenterology and Hepatology CME Released: 06/08/2011; Valid for credit through 06/08/2012
36. Ismail AM, Ziada HN, Sheashaa HA, et al. Decline of viral hepatitis prevalence among asymptomatic Egyptian blood donors: a glimmer of hope. Eur J Intern Med. 2009; 20(5):490-493.
37. Khungar V, Han SH. A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B. Curr Hepat Rep. 2010;9
38. Kumar M, Sarin SK, Hissar S et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134(5): 1376–1384. Lee JK, Shim JH,
39. Kyong-Mi Chang, MD ,Hepatitis B Immunology for Clinicians ,Clinics in Liver Disease - Volume 14, Issue 3 (August 2010) - Copyright © 2010 W. B. Saunders Company

40. Lee HC et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. *Hepatology* 2010; 51: 1577–1583.
41. Lee, H. W. et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. *Hepatology* 51, 415–421 (2010).
42. Liang X, Bi S. Yang W. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. *Vaccine* 2009; 27(47):6550-6557.
43. Liaw Y-F, Suh DJ, Omata M. Available at: www.apasl.info/guidelinesHBV.html (provisional). Accessed 13 April 2008.
44. Liaw, Y. et al. Shorter duration and lower dose of Peginterferon Alfa-2A therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 mG: neptune study (abstract 215). *Hepatology* 521, 429A–430A (2010).
45. Liaw YF, Sheen IS, Lee CM, *et al.* Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. *Hepatology* 2011; 53:62–72
46. Lutgehetmann M, Mancke LV, Volz T, et al. Human chimeric uPA mouse model to study hepatitis B and D virus interactions and preclinical drug evaluation. *Hepatology* 2011; doi: 10.1002/hep.24758.
47. Man-Fong Yuen ;Ching-Lung Lai ;Treatment of chronic hepatitis B:Evolution over two decades .*Jurnal of Gastroenterology and Hepatology* 2011 Foundation and black well publishing Asia pty ltd.
48. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med* 2008; 359(23): 2442–2455
49. Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. *Gastroenterology* 2010; 139:1207–1217.
50. Marcellin P, Bonino F, Lau GK et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. *Gastroenterology* 2009; 136(7): 2169–2179.

51. Merat S, Rezvan H, Nouraie M, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. *Arch Iran Med.* 2009; 12(3):225-231.
52. Milan J. Sonneveld, Harry L. A. Janssen Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? *Liver international* ;Volume 31, Issue Supplement s1, pages 78–84, January 2011
53. Marcellin, P. et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis (abstract 476). *Hepatology* 52, 555A–556A (2010).
54. Mederacke I, Filmann N, Yurdaydin C, et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. *J Hepatol* 2012;56:115-22.
55. Moucari R., Mackiewicz V., Lada O., et al: Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. *Hepatology* 49. (4): 1151-1157.2009.
56. Nassal M. Hepatitis B viruses: reverse transcription a different way. *Virus Res.* 2008;134(1–2):235–249. doi: 10.1016/j.virusres.2007.12.024.
57. Navin Paul and Steven-Huy Han 'Combination Therapy for Chronic Hepatitis B: Current Indications , *Curr Hepat Rep.* 2011 June; 10(2): 98–105.
58. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. *Gut* 2011;60:1109-16.
59. Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. *Intervirology* 2010; 53(1):20-28.
60. Public Health Agency of Canada. http://www.phac-aspc.gc.ca/hcai-iamss/bbp-pts/pdf/hepb_2001_e.pdf. Accessed July 21, 2010
61. Rantala M, van de Laar MJW. Surveillance and epidemiology of hepatitis B and C in Europe—a review. *Euro Surveill.* 2008; 13(21):1-8

62. Richard A. Weisiger MD PhD, Lyman E. Billhartz MD FACP Sleisenger & Fordtran's Gastrointestinal and Liver Disease 2010: 6th Edition .
63. Robert M. Kliegman, MD, Bonita M.D. Stanton, MD, Joseph St. Geme, Nina Schor, MD, PhD and Richard E. Behrman, MD Nelson Textbook of Pediatrics, 19th Edition Hepatitis b.
64. Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int 2011;31:104-10.
65. Ronald D. Miller, MD, Lars I. Eriksson, Lee A. Fleisher, MD, Jeanine P. Wiener-Kronish, MD and William L. Young ,Miller's Anesthesia 2 volume set, 7th Edition
66. Sami S, Korejo R, Bhutta SZ. Prevalence of hepatitis B and hepatitis C: a Jinnah Postgraduate Medical Center experience. J Obstet Gynaecol Res. 2009; 35(3):533-538.
67. Senoo,Haruki., Yoshikawa,Kiwamu, Mezaki,Yoshihiro., Morii Mayako,Fujiwara,Mutsunori ,Regulation of vitamin A homeostasis by the stellate cell(vitamin Astoring cells)system. 2011. Nova Science Publishers Inc.
68. Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol. 2007
69. Sherif R. Z. Abdel-Misih, MD, Mark Bloomston, MD* .Liver Anatomy , Surgical Clinics of NA (2010)
70. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9:274-6.
71. Shouval D, Lai CL, Chang TT et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50(2): 289–295
72. Si Nafa Si Ahmed; Marie Ecochard; Fabien Zoulim End Points of Therapy in Chronic Hepatitis B Expert Rev Gastroenterol Hepatol. 2010;4(1):37-49. © 2010 Expert Reviews Ltd.

73. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. *Hepatology* 2011; 53:763–773..
74. Soon Sun Kim, Jae Youn Cheong, and Sung Won Cho 'Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B', *Gut Liver*. 2011 September; 5(3): 278–287. Published online 2011 August 18.
75. Susan Standring .Gray's Anatomy: The Anatomical Basis of Clinical Practice liver anatomy Copyright © 2007 Elsevier Inc
76. Srisupanant M, Wiwanitkit V. Prevalence of hepatitis B seropositivity among Thai workers in screening program before going abroad. *Ann Hepatol* 2008; 7(4):389.
77. Syed-Mohammed R:Jafri:MD - Anna Suk-Fong Lok:MD; Antiviral therapy for chronic hepatitis B; *Clinics in liver diseases –Vol 14 Issue3* 2010.
78. Tenney, D. J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology* 49, 1503–1514 (2010).
79. U. Protzer and H. Abken .Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B? Received 27 May 2010; Revised 14 July 2010; Accepted 15 July 2010 Copyright © 2010 U. Protzer and H. Abken.
80. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. *J Hepatol*. 2010;52(2):282–284. doi: 10.1016/j.jhep.2009.10.031.
81. V.Rijckborst ; m.J.Sonneveld ,And H.L.A. Janssen: Chronic Hepatitis B – Anti-viral or Immunomodulatory Therapy? *Alimentary Pharmacology and Therapeutics* 2011,Black well publishing.
82. Van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. *Hepatology* 2010; 51:73–80.
83. Van Herck K, Vorsters A, Van Damme P. Prevention of viral hepatitis (B and C) reassessed. *Best Pract Res Clin Gastroenterol*. 2008;22(6):1009-1029.

84. W. Chotiyaputta; A. S. F. Lok .,Endpoints of Hepatitis B Treatment, Journal of Viral Hepatitis J Viral Hepat. 2010;17(10):675-684. © 2010 Blackwell Publishing
85. W. S. Ayoub & E. B. Keeffe Current Antiviral Therapy of Chronic Hepatitis B Posted: 12/11/2011; Alimentary Pharmacology & Therapeutics. 2011;34(10):1145-1158. © 2011 Blackwell Publishing
86. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010; 202(2):192-201.
87. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection - not a vanishing disease in Europe! Hepatology 45, 1331-1332 (2007).
88. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010;7:31-40.
89. World Health Organization. Hepatitis B vaccines: WHO position paper—Recommendations. Vaccine. 2010; 28(3):589-590.
90. Wu IC, Lai CL, Han SH, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010; 51:1185–1189.
91. Yakut M, Seven G, Baran B, et al. Clevudine treatment of chronic delta hepatitis. J Hepatol 2010;52 Suppl 1:473.
92. Yuen MF, Wong DK, Fung J et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135(4): 1192–1199.
93. Yuen MF, Han KH, Um SH, et al. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 2010; 51:767–776.
94. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine. 2008; 26(49):6266-6273. Daniel Grimm, Robert Thimme, and Hubert E. Blum ;HBV life cycle and novel drug targets ' Hepatol Int. 2011 June; 5(2): 644–653 Virology

- 95.** Zou H, Chen Y, Duan Z et al. A retrospective study for clinical outcome of caesarean section on perinatal transmission of hepatitis B virus in infants born to HBeAg positive mothers with chronic hepatitis B (CHB). Presented at: 61st Annual Meeting of the American Association for the Study of Liver Disease. Abstract 235, Boston, MA, USA, 30 October - 2 November 2010.